Introduction
Since the discovery of endothelial progenitor cells (EPC) in 1997 (1) , many researchers have demonstrated the critical role of bone marrow (BM)-derived EPC in postnatal vasculogenesis through pivotal bioactivities, mobilization, homing, migration, differentiation, and proliferation in angiovasculogenic tissues (2) .
Based on this 'dogma', the number of circulating EPC is considered to reflect in vivo vasculogenic activity under pathophysiological conditions. For example, in a physiological feature, the menstrual cycle of human females is reportedly to lead to cyclic fluctuations in the number of circulating EPC (3) .
On the other hand, pathological features, such as cardiovascular risk factors, including coronary heart disease or heart failure (4), diabetes mellitus (5), hypercholesterolemia (6) , and smoking (7) have been reported to decease the number of circulating EPC, indicating an impairment of EPC differentiation and/or mobilization. Recently, chronic inflammatory disorders, such as ulcerative colitis (8) In the present study, we used our established model to further investigate BM-derived EPC bioactivity, particularly its potential for differentiation in LF.
Materials and Methods

Animals
Male C57BL/6J mice were purchased at 6 weeks of age from Crea Japan, Inc. (Tokyo, Japan). All animal experiments were conducted in accordance with the institutional guidelines of Tokai University School of Medicine (Isehara, Japan).
Preparation of the liver fibrosis model
To induce LF, mice were subcutaneously injected with CCl 4 (1 mL/kg body weight) mixed with olive oil every 3 days for 90 days. Control mice were injected with olive oil alone (12) . All mice were sacrificed 2 days after the last injection. After liver tissues were obtained, hematoxylin and eosin (H-E) and Azan staining were performed. In addition, the animals' bodies were weighted, and their spleens also were separately weighed.
Isolation of whole blood mononuclear cells (WBMNCs) and biochemical examinations
Blood samples were collected by intracardiac needle aspiration into heparinized containers. MNCs and plasma were isolated by density-gradient centrifugation (Histopaque 1083; Sigma-Aldrich, Missouri, USA), and erythrocytes were lysed with ammonium chloride. Nucleated cells were washed twice with phosphatebuffered saline/ethylenediaminetetraacetic acid (PBS-EDTA) to eliminate platelets. Biochemical examinations of blood were performed by the Central Clinical Laboratory of Tokai University Hospital (Isehara, Japan) and SRL (Atsugi, Japan). Blood was analyzed for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), alkaline phosphatase (ALP), total bilirubin, total protein, albumin, and hyaluronic acid (HA).
Isolation of BM-KSL cells
A BM stem cell population of KSL cells was isolated by cell sorter, FACS Aria (Becton Dickinson; BD, New Jersey, USA), according to the reported protocol (13), as described below. Whole BM cells were harvested from mouse tibias and femurs as described previously (14), then washed with PBS-EDTA, followed by ammonium chloride hemolysis to remove erythrocytes.
Isolated BM-MNCs were initially stained for 20 min at 4ºC with a lineage-positive antibody cocktail containing CD45R/B220 (BD), TER119 (BD), CD3e (BD), CD11b (BD), Ly-6G, and Ly6C (Gr-1) (BD). After labeling the lineage positive (Lin + ) antibodies with biotin-labeled magnetic beads, cells were subjected to a negative selection process with a magnetic cell sorting system (MACS). Lin-negative (Lin − ) cells were counted and then incubated for 20 min at 4ºC with rat-fluorescein isothiocyanate anti-mouse Ly-6A/E (Sca-1) (BD) and rat-PE CD117 (c-KIT) (BD), washed three times, and resuspended in 20% Iscove's modified Dulbecco medium (GIBCO, Invitrogen, California, USA). Fluorescein isothiocyanateconjugated Sca-1 and phycoerythrin-conjugated c-KIT double-positive cells were then obtained by FACS.
The absolute number of BM stem cells was calculated by multiplying the proportion of KSL cells by the total number of Lin − cells.
EPC colony forming assay
The vasculogenic potential of BM-KSL cells as a stem cell fraction of BM-derived EPCs (15) was assessed using an EPC colony-forming assay. A total of 500 BM stem cells per dish were seeded into a 35-mm hydrophilic tissue culture dishes (Falcon, BD), and EPC colony-forming-units (CFUs) were counted 7 days later. To characterize the EPC colony-derived cells, adherent colonies were stained with Alex 488-conjugated Griffonia simplicifolia isolectin B4 (GS-IB4) (Invitrogen) and 1,1'-Dioctadecyl-3,3,3',3'-tetramethyl indocarbocyanine perchlorate-labeled acetylated low-density lipoprotein (DiI-acLDL) (Biomedical Technologies, Wisconsin, USA) as previously described (5) . In brief, after removing the methylcellulose by gently washing with ice-cold PBS twice, 1 mL of EBM-2 (Lonza, Basel, Switzerland) medium (5% fetal bovine serum) containing 10 μL of DiI-acLDL and 2 μL of Alex-488-conjugated GS-IB4 was added and further incubated for 3-5 h. After staining the colonies with 4',-6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, California, USA), cells were photographed through a fluorescence microscope (IX70; Olympus, Tokyo, Japan).
morphologically detect two types of EPC-CFUs, that is, primitive EPC-CFU and definitive EPC-CFU with small round and large spindle cells, respectively as previously described (16) (Figure 2 ). Both types of EPC-CFUs featured typical endothelial aspects of acLDL-DiI uptake and isolectin B4-FITC binding ( Figures 2C and 2F ).
In the EPC-colony forming assay of BM-KSL cells, the number of definitive EPC-CFU (p < 0.0001) and total EPC-CFU (p < 0.05) significantly decreased in LF mice, compared with controls, although primitive EPC-CFU did not differ between groups (Figure 3 ). These findings indicate that the differentiation potentials of BM-KSL cells into endothelial lineage are impaired in LF mice.
Attenuated EPC differentiation potential in circulation of LF mice
In the EPC-colony forming assay of WB-MNCs, the number of definitive EPC-CFU (p < 0.005) and total EPC-CFU (p < 0.01) significantly decreased in LF mice, compared with controls, although primitive EPC-colony forming cells did not differ between groups (Figure 4 ).
Discussion
In the current study, we successfully prepared an LF-
Results
Assessment of LF-mice model
In control mice, surfaces of the liver sections were smooth, and fatty changes, characterized by large droplets in hepatocytes, were observed ( Figures 1A  and 1B) . On the other hand, in the LF group, surfaces of the liver sections were irregular, bridging fibrosis, pseudolobule formation, and micronodular formation ( Figures 1C and 1D) . Spleens of CCl 4 injected mice were larger than those of the control group (Table 1 ). The ratio of spleen weight/body weight was significantly increased in CCl 4 mice, compared with control mice (p < 0.005). Serum AST, ALT, and ALP were significantly increased in CCl 4 mice compared with control mice (p < 0.005) ( Table 2 ). However, there were no significant difference in mice serum γ-GTP, total bilirubin, total protein, albumin, and HA levels (data not shown). Finally, LF was clearly evident in all mice injected with CCl 4 .
Impaired commitment and differentiation potentials of BM-KSL cells in LF mice
EPC colony forming activity of BM-KSL cells was performed by EPC colony-forming assay to mice model via CCl 4 administration to evaluate EPC kinetics in LF using an EPC colony forming assay. Results showed that in BM and within the circulation of LF mice, the frequency of primitive colony forming EPC was not attenuated, but that of definitive colony forming EPC was significantly decreased, resulting in a decreased number of whole colonies forming EPC in LF-mice versus controls. These findings indicate that the function of EPC differentiation is downregulated in LF mice.
Chronic inflammatory LF induces vascular remodeling exerted by proangiogenic growth factors produced under hypoxic conditions via inadequate blood supply triggered by fibrotic tissue in humans (16) . Based on the progression of LF, the replacement of functional hepatocytes with an excess amount of extracellular matrix is considered to decrease the production of proangiogenic growth factors or cytokines, such as vascular endothelial growth factor (17), cyclooxygenase-2-induced eicosanoids (18) , hepatocyte growth factor (19) , and thrombopoietin (20) .
Various studies have demonstrated the pivotal roles of BM-derived EPCs, including their role in postnatal vasculogenesis, that is, mobilization, differentiation, and in foci recruitment, and shown that these cells are upregulated by proangiogenic growth factors, cytokines, and hormones (2) . Previous reports show that EPC induce vasculogenesis and repair the injured tissues in several diseases (21, 22) . One of the mechanisms of this effect is that EPCs express several growth factors that exert paracrine effects for tissue regeneration, including hepatocyte growth factor, vascular endothelial growth factor, and transforming growth factor-alpha (23) . Therefore, it is predicted that disturbed EPC differentiation might give rise to inadequate production for tissue regeneration, although the productivity of growth factors accompanying EPC differentiation need to be investigated.
Alternatively, it has recently been reported that the physiological homeostasis of EPC function is impaired in patients with diabetes (5), hypertension (24) , hyperlipidemia (6), rheumatic disease (9), Alzheimer disease (11), aging, and smoking (7). In these conditions, oxidative stress is a key factor in inducing senescence or apoptosis of EPCs, resulting in impairments of physiological functions of EPC (25) . Also, oxidative stress has been demonstrated to be a major inducer of pathological progression into LF in chronic liver disease as well (26) . Therefore, in the present study, it is understandable that oxidative stress causing LF may impair EPC differentiation potential, as previously discussed in diabetes (16, 27) .
A therapeutic vascular improvement induced by using EPCs for chronic lower-limb ischemia including arteriosclerosis obliterans or Burger's disease, as well as myocardial infarction or angina pectoris, has been identified (28) . In the field of liver regeneration therapy, autologous bone marrow cell infusion therapy, using 81 MNC (so-called non-selected EPCs), or selected EPCs (CD34 + or CD133 + ) has been used to treat liver cirrhosis patients in clinical studies, and favorable therapeutic efficacy has been reported (29, 30) . However, although accumulating evidence has indicated that EPC therapy may be a useful treatment for liver cirrhosis patients, there have been few reports on EPC kinetics during the development of LF.
Our study demonstrated that the homeostasis of EPC function was disrupted in LF, indicating a weakened regenerative capability. Given these results, it appears necessary to precisely and adequately investigate the efficacy of autologous bone marrow cell infusion using 'naïve EPCs' or to develop a novel strategy for improvement of EPC differentiation potential. Regarding this, G-CSF is reported to promote VEGF secretion from neutrophil for angiogenesis (31) . Accordingly, the administration of G-CSF may be considered as one of strategies to repair its potential by induction of EPC differentiation as well as mobilization, because VEGF augments EPC differentiation and mobilization (32) . The transplantation of EPCs after G-CSF administration may further enhance the recovery from LF. Alternatively, ex vivo culture system to improve the impaired EPC function, when successfully developed, might be another promising strategy.
In conclusion, LF exhibits impaired EPC commitment and differentiation potentials, providing information applicable not only for the pathological diagnosis, but also for the development of an effective EPC therapy.
